Functional Analysis of BARD1 Missense Variants on Homology‐Directed Repair in Ovarian and Breast Cancers
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.23829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Wenjing Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Mutation, Missense, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: This work was supported by Beijing JST Research Funding (ZR-2022016 to W.L.) and National Natural Science Foundation of China (32200064 to T.W.)..
Abstract (Originalsprache)
Women with germline BRCA1 mutations face an increased risk of developing breast and ovarian cancers. BARD1 (BRCA1 associated RING domain 1) is an essential heterodimeric partner of BRCA1, and mutations in BARD1 are also associated with these cancers. While BARD1 mutations are recognized for their cancer susceptibility, the exact roles of numerous BARD1 missense mutations remain unclear. In this study, we conducted functional assays to assess the homology‐directed DNA repair (HDR) activity of all BARD1 missense substitutions identified in 55 breast and ovarian cancer samples, using the real‐world data from the COSMIC and cBioPortal databases. Seven BARD1 variants (V85M, P187A, G491R, R565C, P669L, T719R, and Q730L) were confirmed to impair DNA damage repair. Furthermore, cells harboring these BARD1 variants exhibited increased sensitivity to the chemotherapeutic drugs, cisplatin, and olaparib, compared to cells expressing wild‐type BARD1. These findings collectively suggest that these seven missense BARD1 variants are likely pathogenic and may respond well to cisplatin‐olaparib combination therapy. This study not only enhances our understanding of BARD1's role in DNA damage repair but also offers valuable insights into predicting therapy responses in patients with specific BARD1 missense mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
- State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.
- National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital), Beijing, China.
- Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing, China.
- Department of Pathology, Chuzhou First People's Hospital, Anhui, China.
- School of Life Science, Bengbu Medical University, Anhui, China.
Förderung
- This work was supported by Beijing JST Research Funding (ZR-2022016 to W.L.) and National Natural Science Foundation of China (32200064 to T.W.).
Zitieren
APA
Li, W., Chen, G., Wang, Y., Jiang, Y., Wu, N., Hu, M., Wu, T., & Yue, W. (2025). Functional Analysis of BARD1 Missense Variants on Homology‐Directed Repair in Ovarian and Breast Cancers. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23829
Vancouver
Li W, Chen G, Wang Y, Jiang Y, Wu N, Hu M, et al. Functional Analysis of BARD1 Missense Variants on Homology‐Directed Repair in Ovarian and Breast Cancers. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23829
BibTeX
@article{Li2025,
author = {Li, Wenjing and Chen, Guansheng and Wang, Yongjun and Jiang, Yuening and Wu, Nanlin and Hu, Mingjie and Wu, Taju and Yue, Wei},
title = {Functional Analysis of BARD1 Missense Variants on Homology‐Directed Repair in Ovarian and Breast Cancers},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.23829}
}
EUVIMED